Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma

Hematological Oncology

Volumn 30, Issue 3, 2012, Pages 131-136

  Tsirakis, George ^a   Pappa, Constantina A ^b   Kanellou, Peggy ^a   Stratinaki, Maria A ^b   Xekalou, Athina ^a   Psarakis, Fotios E ^b   Sakellaris, George ^a   Alegakis, Athanasios ^c   Stathopoulos, Efstathios N ^a   Alexandrakis, Michael G ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Angiogenesis; Cytokines; Multiple myeloma

Indexed keywords

ANGIOGENIN; BETA 2 MICROGLOBULIN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR AB;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BONE MARROW; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-6; MALE; MICROVESSELS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RIBONUCLEASE, PANCREATIC;

EID: 84866279444     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1014     Document Type: Article

References (34)

1. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
2. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398-1401.
3. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210-217.
4. Cao Y, Cao R, Hedlund EM. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signalling pathways. J Mol Med. 2008; 86: 785-789.
5. Wiens KM, Lee HL, Shimada H, Metcalf AE, Chao MY, Lien CL. Platelet-derived growth factor receptor beta is critical for zebrafish intersegmental vessel formation. PLoS One 2010; 5(6): e11324.
6. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 15(22): 1276-1312.
7. Cao R, Bråkenhielm E, Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002; 16: 1575-1583.
8. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007; 117: 2766-2777.
9. Verstovsek S, Kantarjian H, Aguayo A, et al. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 2001; 114: 290-295.
10. Weiner HL, Weiner LH, Swain JL. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science 1987; 237: 280-282.
11. Hu GF, Chang SI, Riordan JF, Vallee BL. An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci U S A 1991; 88: 2227-2231.
12. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993; 197: 682-687.
13. Offersen BV, Borre M, Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003; 39: 881-890.
14. Alexandrakis MG, Passam FJ, Ganotakis E, et al. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 2004; 42: 1122-1126.
15. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
16. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-29.
17. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-118.
18. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983; 55: 439-547.
19. Kara IO, Sahin B, Gunesacar R, Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther 2006; 23: 635-645.
20. Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009; 205: 11-20.
21. Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J 2009; 23: 153-163.
22. McCarty MF, Somcio RJ, Stoeltzing O, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007; 117: 2114-2122.
23. Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-341.
24. Alexandrakis MG, Passam FH, Boula A, et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003; 82: 19-23.
25. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162-169.
26. Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010; 46: 420-429.
27. Kitami Y, Inui H, Uno S, Inagami T. Molecular structure and transcriptional regulation of the gene for the platelet-derived growth factor alpha receptor in cultured vascular smooth muscle cells. J Clin Invest 1995; 96: 558-567.
28. Alexandrakis MG, Passam FH, Sfiridaki A, Kyriakou DS, Petreli E, Roussou P. Elevated serum angiogenin in multiple myeloma. Hematol J 2003; 4: 454-455.
29. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol 1994; 172: 171-175.
30. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137: 560-568.
31. Strydom DJ. The angiogenins. Cell Mol Life Sci 1998; 54: 811-824.
32. Sezer O, Niemöller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000; 79: 574-577.
33. Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235-239.
34. Sucak GT, Aki SZ, Yüzbaşioǧlu B, et al. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma 2011; 52: 1281-1289.